Abstract:Background: Several trials combining microbiome-based interventions with immune checkpoints inhibitors (ICI) are currently underway. Previous studies showed the potential of fecal microbiota transplant (FMT) to circumvent secondary anti-PD-1 resistance or improve first-line anti-PD-1 response in patients with advanced melanoma. Whether FMT can be used safely in combination with anti-PD-1/anti-CTLA-4 (dual ICI) and its impact on the microbiome composition remain unknown. Here, we report results from combining FMT with dual ICI in previously untreated patients (pts) with advanced melanoma (NCT04951583). Methods: 20 pts with previously untreated advanced melanoma were included. FMT from healthy donors was administered in oral capsules after bowel preparation 1 week prior to start of dual ICI. A total of 6 different donors were used. The primary endpoint was safety. Secondary endpoints included objective response rate (ORR) and microbiome shift using shotgun metagenomic sequencing. Longitudinal serum Il1rl1 gene product (sST2) epithelial integrity marker was measured. Stool from pts before and after FMT were transplanted into avatar mice (MCA-205 or B16 OVA) and then treated with dual ICI. Results: In the 20 pts enrolled, 13 (65%) were male and median age was 56. Median follow-up was 6 months (range (IQR) 3.23; 12.33). FMT alone resulted in grade 1 toxicities. Grade 1-2 immune related adverse event (irAE) occurred in 80% of pts and 65% developed grade >3 irAE. Diarrhea or colitis was the most frequent grade 3 irAE occurring in 4 (20%). 2 pts developed myocarditis (grade 3 and grade 4, respectively). 6 (30%) pts completed all 4 cycles of dual ICI. 6 (43%) pts that developed irAE grade 3 received FMT from the same donor. ORR was 70% (2 complete responses (CR) and 12 partial responses (PR)). Two pts died; one from unknown cause in PR and one from disease progression. Microbiome profiling beta-diversity analyses revealed separate clustering of responders (R) and non-responders (NR) post-FMT (p=0.024). We observed an enrichment of Prevotella copri, Ruminoccocaceae and Eubacterium in R pts post-FMT. Pts who developed colitis were found to have a higher level of sST2 in plasma 1 week after FMT in comparison to those who did not develop colitis (p<0.05). In both avatar murine tumor models, microbiome composition with R pts' feces (without ICI) 1 month post-FMT had reduced tumor growth compared to those treated with respective NR pt feces. Additionally, dual ICI led to significantly improved tumor control in mice treated with R pts' feces post-FMT(p<0.005). Conclusions: The addition of FMT to dual ICI resulted in significant irAEs that occurred earlier, although the proportion was similar to previously described literature, with encouraging ORR. Metagenomic analysis depicted differences in the microbiome profiles of R compared to NR pts post FMT. These results support the study of FMT and immunotherapy in the randomized setting. Citation Format: Sreya Duttagupta, Meriem Messaoudene, Rahima Jamal, Catalin Mihalcioiu, Karl Belanger, John Lenehan, Wiam Belkaid, Seema Nair Parvathy, Jade Maillou, Yongjia Hu, Mayra Ponce, Taiki Hakozaki, Eder Mendez Salazar, Michael Silverman, Saman Maleki Vareki, Arielle Elkrief, Bertrand Routy. Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr CT258.

The Use of Fecal Microbiota Transplant in Overcoming and Modulating Resistance to Anti-PD-1 Therapy in Patients with Skin Cancer

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Efficacy of fecal microbiota transplantation in patients with anti-PD-1–resistant/refractory gastrointestinal cancers.

Fecal microbiota transplantation and its repercussions in patients with melanoma refractory to anti-PD-1 therapy: scope review

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.

Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor

Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer

Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients

Abstract CT258: Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial)

Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report

The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients

Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial

The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors

Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

The Gut Microbiome is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer